2 options
Benign prostatic hyperplasia (BPH) management in primary care--screening and therapy / Mark Helfand, Tara Muzyk, Mark Garzotto.
- Format:
- Book
- Government document
- Series:
- Evidence synthesis pilot program (Series)
- Evidence synthesis pilot program
- Language:
- English
- Subjects (All):
- Prostatectomy.
- Prostate--Hypertrophy.
- Prostate.
- Prostate--Cancer--Diagnosis.
- Outcome assessment (Medical care).
- Prostatic Hyperplasia--drug therapy.
- Adrenergic alpha-1 Receptor Antagonists--therapeutic use.
- 5-alpha Reductase Inhibitors--therapeutic use.
- Drug Therapy, Combination.
- Treatment Outcome.
- Prostatic Hyperplasia.
- Medical Subjects:
- Prostatic Hyperplasia--drug therapy.
- Adrenergic alpha-1 Receptor Antagonists--therapeutic use.
- 5-alpha Reductase Inhibitors--therapeutic use.
- Drug Therapy, Combination.
- Treatment Outcome.
- Prostatectomy.
- Prostatic Hyperplasia.
- Genre:
- technical reports.
- Technical reports
- Technical reports.
- Physical Description:
- 1 online resource (31 pages) : illustrations.
- Other Title:
- At head of title: Comparative effectiveness review
- Place of Publication:
- [Washington, D.C.] : Dept. of Veterans Affairs, Health Services Research & Development Service, [2007]
- Summary:
- Benign prostatic hyperplasia (BPH) causes urinary hesitancy and intermittency, weak urine stream, nocturia, frequency, urgency, and the sensation of incomplete bladder emptying. These symptoms, collectively called "lower urinary tract symptoms, " or LUTS, can significantly reduce quality of life. Men with no symptoms or mild symptoms (AUA Symptom Index [SI] score of <7 points), and those who tolerate moderate symptoms well, may be managed without pharmacotherapy ("watchful waiting"). For those who have moderate or severe symptoms, medical treatments include alpha-1-selective adrenergic receptor (a-1-AR) antagonists, 5-alpha-reductase inhibitors (5-aRIs), or a combination therapy with one drug from each of these classes. This report addresses the following questions about treatment for BPH: For patients with BPH, what are the comparative benefits, harms, and efficacy of combination therapy with a 5-alpha-reductase inhibitor plus an alpha blocker versus either treatment alone? What are the comparative efficacy and harms of alpha-1-adrenergic antagonists? Are there subgroups of patients based on demographics (age, racial groups), other medications, or co-morbidities for which one treatment is more effective or associated with fewer adverse events?
- Notes:
- Title from PDF title screen (VA.gov, viewed Dec. 6, 2010).
- "February 2007."
- Includes bibliographical references.
- OCLC:
- 696313784
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.